New GMP Analytical Capability

Kulmbach - London, 1 October, 2018

Today, LGC Axolabs announces a significant investment at its site at Kulmbach, Germany, to expand the capacity of its specialist therapeutic oligonucleotide development solutions business and create a new GMP analytical capability. 

Due to open in February 2019, the new 800m² labs comprise additional bioanalysis and synthetic chemistry labs as well as a new GMP CMC analytical capability for batch release testing of oligonucleotide-based drug substances and drug products in the EU.      

The new facility will complement LGC’s established bioanalytical and CMC analytical labs in the UK, as well as their oligonucleotide cGMP manufacture and CMC labs in Petaluma, California which is due to run its first cGMP manufacturing campaigns later this year.  LGC now offers its clients a truly global platform to support drug development and manufacturing.

Hans-Peter Vornlocher, Managing Director, Research at LGC Axolabs, said, “This investment provides a platform for growth of our oligonucleotide therapeutics development activities, expanding our total site capacity to around 4,500m2 and to around 100 scientists.  We are also glad to be able to add GMP analytical services as a new dimension to our biology, synthetic chemistry and other analytical services”.

David Griffiths, Managing Director, Pharma & Health Solutions, LGC, said, “We’re excited about this expansion which not only supports growth of our Kulmbach site but is also part of a larger international growth strategy for LGC’s drug development solutions business giving access and greater flexibility for our clients”. The investment in Kulmbach supplements LGC’s announcement last year of further investment at its Petaluma site as well as the recent completion of the first phase in a long-term major investment to expand capacity of its bioanalytical labs in Fordham, UK.